v3.26.1
Schedule of Company’s Segments Including a Reconciliation to Income Before Taxes (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Total consolidated revenue $ 2,175,485   $ 1,863,654   $ 4,190,710 $ 3,500,839
Depreciation and amortization 145,573   169,737   288,271 404,199
Provision for income taxes 56,154     56,154
Net income (loss) from continuing operations 888,740   (1,543,205)   (4,650,611) (3,035,476)
Loss on disposal   (1,534,517)   (1,534,517)
Loss on discontinued operations   (541,247)   (16,452,562)
Net loss attributable to Invo Bioscience, Inc 888,740 $ (5,539,351) (3,618,969) $ (17,403,586) (4,650,611) (21,022,555)
[custom:SegmentAssets-0] 6,268,348   8,716,325   6,268,348 8,716,325
Operating Segments [Member]            
Segment Reporting [Line Items]            
Total segment revenue 2,177,861   1,872,654   4,205,086 3,514,339
Elimination of intersegment revenue (2,376)   (9,000)   (14,376) (13,500)
Total consolidated revenue 2,175,485   1,863,654   4,190,710 3,500,839
Cost of revenue 1,417,675   1,114,193   2,705,074 2,178,420
Sales and marketing 19,652   12,263   40,765 25,237
General and administrative 457,579   330,774   972,507 637,875
Research and development        
Impairment loss   1,397,353      
Depreciation and amortization 35,127   148,870   72,379 363,757
Total segment profit (loss) 245,453   (1,139,798)   399,986 (1,101,802)
Total segment profit (loss) 245,453   (1,139,798)   399,986 (1,101,802)
Total segment profit (loss) 2,411,771   1,887,479   (1,356,286) 1,902,575
Interest expense (177,227)   (440,596)   (357,550) (440,596)
Unallocated corporate expenses (1,535,103)   (1,850,290)   (3,280,607) (3,087,814)
Income (loss) from continuing operations before income taxes 944,894   (1,543,205)   (4,594,457) (2,727,637)
Provision for income taxes 56,154     56,154
Net income (loss) from continuing operations 888,740   (1,543,205)   (4,650,611) (2,727,637)
Loss on disposal   (1,534,517)   (1,534,517)
Loss on discontinued operations   (541,247)   (16,760,401)
Net loss attributable to Invo Bioscience, Inc 888,740   (3,618,969)   (4,650,611) (21,022,555)
Operating Segments [Member] | Revenue From External Customers [Member]            
Segment Reporting [Line Items]            
Total segment revenue 2,175,485   1,863,654   4,190,710 3,500,839
Operating Segments [Member] | Inter Segment Revenue [Member]            
Segment Reporting [Line Items]            
Total segment revenue 2,376   9,000   14,376 13,500
Fertility Clinic Services [Member]            
Segment Reporting [Line Items]            
[custom:SegmentAssets-0] 6,238,540   8,679,223   6,238,540 8,679,223
Fertility Clinic Services [Member] | Operating Segments [Member]            
Segment Reporting [Line Items]            
Total segment revenue 2,167,785   1,832,094   4,150,018 3,453,647
Elimination of intersegment revenue    
Total consolidated revenue 2,167,785   1,832,094   4,150,018 3,453,647
Cost of revenue 1,357,527   1,111,129   2,639,775 2,171,372
Sales and marketing 19,652   12,263   40,765 25,237
General and administrative 457,579   330,774   972,507 637,875
Research and development        
Impairment loss   1,397,353      
Depreciation and amortization 32,696   146,439   67,516 358,895
Total segment profit (loss) 300,331   (1,165,863)   429,455 (1,137,084)
Total segment profit (loss) 300,331   (1,165,863)   429,455 (1,137,084)
Fertility Clinic Services [Member] | Operating Segments [Member] | Revenue From External Customers [Member]            
Segment Reporting [Line Items]            
Total segment revenue 2,167,785   1,832,094   4,150,018 3,453,647
Fertility Clinic Services [Member] | Operating Segments [Member] | Inter Segment Revenue [Member]            
Segment Reporting [Line Items]            
Total segment revenue    
INVOcell Device [Member]            
Segment Reporting [Line Items]            
[custom:SegmentAssets-0] 29,809   37,102   29,809 37,102
INVOcell Device [Member] | Operating Segments [Member]            
Segment Reporting [Line Items]            
Total segment revenue 10,076   40,560   55,068 60,692
Elimination of intersegment revenue (2,376)   (9,000)   (14,376) (13,500)
Total consolidated revenue 7,700   31,560   40,692 47,192
Cost of revenue 60,147   3,064   65,299 7,048
Sales and marketing    
General and administrative    
Research and development        
Impairment loss        
Depreciation and amortization 2,431   2,431   4,862 4,862
Total segment profit (loss) (54,878)   26,065   (29,469) 35,282
Total segment profit (loss) (54,878)   26,065   (29,469) 35,282
INVOcell Device [Member] | Operating Segments [Member] | Revenue From External Customers [Member]            
Segment Reporting [Line Items]            
Total segment revenue 7,700   31,560   40,692 47,192
INVOcell Device [Member] | Operating Segments [Member] | Inter Segment Revenue [Member]            
Segment Reporting [Line Items]            
Total segment revenue $ 2,376   $ 9,000   $ 14,376 $ 13,500